The Gila monster is a slow, heavy lizard native to the deserts of the American southwest. It eats a few large meals a year and survives the gaps on stored fat. Its venom had been studied since the 1980s because of a clinical observation: people bitten by one sometimes developed inflammation of the pancreas, which suggested something in the venom was acting on that organ.
In 1992 John Eng, an endocrinologist working at the Veterans Affairs hospital in the Bronx, isolated a 39-amino-acid peptide from the venom and named it exendin-41.
What made it interesting
Exendin-4 shares roughly 53% of its sequence with human GLP-1, the gut hormone that stimulates insulin release after meals. The overlap was enough that it bound and activated the human GLP-1 receptor. The difference was enough that the enzyme DPP-4, which destroys native GLP-1 within two minutes, could not cut it. Exendin-4 lasted hours.
That combination, same receptor, much longer life, is the entire premise of the drug class that followed. A molecule that mimics GLP-1 but survives in circulation can lower glucose and reduce appetite for an extended period from a single injection.
The thirteen years in between
Years after the 1992 isolation
Golden Goose Award citation [1]; FDA approval record [2]. Chart by TrueLab Care.
The part of the story that rarely gets told is how close it came to not happening. Eng's employer saw no commercial value in a lizard peptide and declined to patent it. He filed the application himself in 1993 and spent the next three years approaching pharmaceutical companies, none of which were interested1.
In 1996, at an American Diabetes Association meeting in San Francisco, he caught the attention of a scientist from Amylin Pharmaceuticals, a small company that licensed the compound. A synthetic version, exenatide, went through clinical development and was approved by the FDA in 2005 as the first GLP-1 receptor agonist2. Thirteen years from isolation to licence, four of them spent looking for anyone who would take it.
From hours to a week
Exenatide needed injecting twice daily. The next two decades of chemistry were spent extending that. Liraglutide added a fatty-acid chain to bind albumin and reached once daily. Semaglutide refined the chain and the peptide backbone to reach once weekly3. Tirzepatide added a second receptor. Retatrutide added a third.
Every one of those molecules is a descendant of the observation that a lizard's venom contained something that behaved like a durable GLP-1. None of them would exist in their current form if the first had not demonstrated that extended GLP-1 receptor agonism was both possible and useful in humans.
Why the story matters for a research reader
Two lessons travel well.
The first is about provenance. Exendin-4 was a natural product, found by looking carefully at a biological curiosity, and it took a decade of synthesis and trials to become a drug. The modern compounds are entirely synthetic and were designed, not found. The literature for each is correspondingly different: the lizard peptide has a discovery story, the designed peptides have design papers.
The second is about time. Thirteen years from a validated mechanism to an approved drug, for a compound that worked. Retatrutide's discovery paper was published in 2022; its filing is planned for 2027. That is fast by the standards of the class, and it is still half a decade.